Abstract
Kidney transplant recipients are at high risk of progressive bone loss and low-energy fractures in the years following transplantation. Marine n-3 polyunsaturated fatty acids (n-3 PUFA) supplementation may have beneficial effects on bone strength. The Omega-3 fatty acids in Renal Transplantation (ORENTRA) trial was an investigator initiated, randomized, placebo-controlled trial investigating the effects of marine n-3 PUFA supplementation after kidney transplantation. Effects of supplementation on bone mineral density (BMD) and calcium metabolism were pre-defined secondary endpoints. Adult kidney transplant recipients (n = 132) were randomized to 2.6 g marine n-3 PUFA supplement or olive oil (control) from 8 to 52 weeks post-transplant. Dual energy X-ray absorptiometry was performed to assess changes in bone mineral density of hip, spine, and forearm, as well as trabecular bone score (TBS) of the lumbar spine. Student’s t test was used to assess between-group differences. There were no differences in ∆BMD between the two groups (intervention vs. control) at lumbar spine (−0.020 ± 0.08 vs. −0.007 ± 0.07 g/cm 2, p = 0.34), total hip (0.001 ± 0.03 vs. −0.005 ± 0.04, p = 0.38), or other skeletal sites in the intention-to-treat analyses. There was no difference in the change in TBS score (0.001 ± 0.096 vs. 0.009 ± 0.102, p = 0.62). Finally, no effect on biochemical parameters of mineral metabolism was seen. Results were similar when analyzed per protocol. In conclusion, we found no significant effect of 44 weeks of supplementation with 2.6 g of marine n-3 PUFA on BMD in kidney transplant recipients.
Original language | English |
---|---|
Article number | 2361 |
Journal | Nutrients |
Volume | 13 |
Issue number | 7 |
ISSN | 2072-6643 |
DOIs | |
Publication status | Published - 10 Jul 2021 |
Keywords
- Absorptiometry, Photon
- Adult
- Aged
- Biomarkers/blood
- Bone Density/drug effects
- Calcium/blood
- Denmark
- Dietary Supplements/adverse effects
- Docosahexaenoic Acids/administration & dosage
- Double-Blind Method
- Drug Combinations
- Eicosapentaenoic Acid/administration & dosage
- Female
- Humans
- Kidney Transplantation/adverse effects
- Male
- Middle Aged
- Osteoporosis/etiology
- Osteoporotic Fractures/etiology
- Time Factors
- Treatment Outcome